1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
It's been a challenging year for NovoCure (NASDAQ: NVCR), an oncology-focused biotech. The stock is down by 35% since early January. Though marketwide issues probably didn't help, NovoCure mostly has itself to blame for its year-to-date performance. Its shares declined after a disappointing fourth-quarter update.Still, the stock could have significant upside potential. NovoCure's average price target on Wall Street is $32.57, according to Yahoo! Finance. That implies it could jump by almost 70% from its current levels. Should investors be as bullish as the Street on NovoCure?Image source: Getty Images.Continue reading
It's been a challenging year for NovoCure (NASDAQ: NVCR), an oncology-focused biotech. The stock is down by 35% since early January. Though marketwide issues probably didn't help, NovoCure mostly has itself to blame for its year-to-date performance. Its shares declined after a disappointing fourth-quarter update.
Still, the stock could have significant upside potential. NovoCure's average price target on Wall Street is $32.57, according to Yahoo! Finance. That implies it could jump by almost 70% from its current levels. Should investors be as bullish as the Street on NovoCure?
Image source: Getty Images.
